HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): John M. Armitage Bartley P. Griffith Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Armitage, J. M. Articles by Fricker, F. J. Search for Related Content PubMed PubMed Citation Articles by Armitage, J. M. Articles by Fricker, F. J.

J Thorac Cardiovasc Surg 1995;109:60-65
© 1995 Mosby, Inc.

CARDIAC AND PULMONARY REPLACEMENT

Critical issues in pediatric lung transplantation

Pittsburgh, Pa.

Address for reprints: John M. Armitage, MD, Associate Professor of Surgery, University of Pittsburgh Medical Center, C700 PUH-UPMC, 200 Lothrop St., Pittsburgh, PA 15213.

Abstract

Forty children (aged 1 to 18 years, 27 female and 13 male) have undergone heart-lung (21), double lung (17), and single lung (2) transplant procedures at our center from 1985 through April 1994. The indications for transplantation have been diverse, primary pulmonary hypertension (10), cystic fibrosis (11), congenital heart disease (10), arteriovenous malformation (3), emphysema (1), graft-versus-host disease (1), rheumatoid lung (1), cardiomyopathy (1), desquamative interstitial pneumonitis (1), and Proteus syndrome (1). The actuarial 1-year survival was 73% (mean follow-up 2 years). One-year actuarial survival for disease groups ranged from 60% for cystic fibrosis to 90% for congenital heart disease. We have identified six issues critical to the patient and programatic survival of pediatric lung transplantation. Our experience and management strategies in these areas are reviewed. Cytomegalovirus: Cytomegalovirus disease developed in six of eight patients with cytomegalovirus mismatching (donor+/recipient -) and in seven of 32 patients who survived more than 30 days (23%). All but cytomegalovirus donor -/recipient-patients were treated with ganciclovir for 4 weeks after transplantation. Obliterative bronchiolitis: Obliterative bronchiolitis developed in seven of 32 (25%) patients who survived more than 30 days. Obliterative bronchiolitis was manifest within the first posttransplantation year as a rapid decline in small airway function. Aggressive augmentation of immunosuppression has been used with little success.Posttransplantation lymphoproliferative disease: Posttransplantation lymphoproliferative disease developed in five of 32 (15%) patients who survived more than 30 days developed. One patient died (17% mortality) despite retransplantation. In four patients the disease resolved with reduction in immunosuppression alone, and one required the addition of interferon alfa. Cystic fibrosis: We have changed our management strategies to avoid triple drug immunosuppression, perioperative blood and bronchial cultures, aggressive antimicrobial therapy, and exclusion of patients with panresistant organisms; this has resulted in elimination of infectious mortalities thus far in the pediatric cystic fibrosis group. Airways: In 21 heart-lung recipients with tracheal anastomoses we have had no airway complications. The double and single lung transplant recipients accounted for 34 bronchial and one tracheal anastomoses. Three (9%) bronchial stenoses developed. Two were treated with silicone stents and one with balloon dilation. Finances: The average charge for lung transplant evaluation was $18,000 and for transplantation, $175,000. (J THORAC CARDIOVASC SURG 1995;109:60-5)

This article has been cited by other articles:

				M. Benkerrou, J.-P. Jais, V. Leblond, A. Durandy, L. Sutton, P. Bordigoni, J. L. Garnier, J. Le Bidois, F. Le Deist, S. Blanche, et al. Anti-B-Cell Monoclonal Antibody Treatment of Severe Posttransplant B-Lymphoproliferative Disorder: Prognostic Factors and Long-Term Outcome Blood, November 1, 1998; 92(9): 3137 - 3147. [Abstract] [Full Text] [PDF]

				International Guidelines for the Selection of Lung Transplant Candidates Am. J. Respir. Crit. Care Med., July 1, 1998; 158(1): 335 - 339. [Full Text] [PDF]